SPR719

SPR719 (VXc-486) is an orally active gyrase B inhibitor, with bactericidal activity. SPR719 potently inhibits multiple agent-sensitive isolates and drug-resistant isolates of Mycobacterium tuberculosis, with MICs of 0.03 to 0.30 μg/ml and 0.08 to 5.48 μg/ml, respectively. SPR719 is promising for research of lung disease caused by non-tuberculous mycobacteria (NTM) [1][2][3][4].

Product Specifications

CAS Number

[1384984-18-2]

Product Name Alternative

VXc-486

UNSPSC

12352005

Target

Bacterial; Topoisomerase

Type

Reference compound

Related Pathways

Anti-infection; Cell Cycle/DNA Damage

Applications

COVID-19-anti-virus

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/vxc-486.html

Purity

99.39

Solubility

DMSO : 20 mg/mL (ultrasonic; adjust pH to 2 with HCl)

Smiles

O=C(NC1=NC2=CC(C3=CN=C(C(C)(O)C)N=C3)=C(F)C([C@@H]4OCCC4)=C2N1)NCC

Molecular Formula

C21H25FN6O3

Molecular Weight

428.46

References & Citations

[1]Locher CP, et al. A novel inhibitor of gyrase B is a potent drug candidate for treatment of tuberculosis and nontuberculosis mycobacterial infections. Antimicrob Agents Chemother. 2015 Mar;59 (3) :1455-65.|[2]Pidot SJ, et al. In vitro activity of SPR719 against Mycobacterium ulcerans, Mycobacterium marinum and Mycobacterium chimaera. PLoS Negl Trop Dis. 2021 Jul 26;15 (7) :e0009636.|[3]Aragaw WW, et al. In Vitro Resistance against DNA Gyrase Inhibitor SPR719 in Mycobacterium avium and Mycobacterium abscessus. Microbiol Spectr. 2022 Feb 23;10 (1) :e0132121.|[4]Cotroneo N, et al. In vitro activity and in vivo efficacy against non-tuberculous mycobacteria of SPR719, the active moiety of the novel oral benzimidazole prodrug SPR720[J]. bioRxiv, 2022: 2022.12. 08.519697.